US Pharma MarketingChutes & Ladders—Former FDA leader takes new biotech Turn
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Stephen Hahn, M.D., who served as the commissioner of the FDA for just over a year during the first Trump administration, is taking his extensive regulatory expertise to Turn Therapeutics. As executive clinical and regulatory lead, Hahn will guide the regulatory strategy for GX-03, Turn’s topical eczema treatment that is currently in a phase 2 study. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical…
Stephen Hahn, M.D., who served as the commissioner of the FDA for just over a year during the first Trump administration, is taking his extensive regulatory expertise to Turn Therapeutics. As executive clinical and regulatory lead, Hahn will guide the regulatory strategy for GX-03, Turn’s topical eczema treatment that is currently in a phase 2 study.
Source: FierceBiotech